Louis | ManUp & WomanUp Targeted Fat Loss with AOD-9604 AOD-9604, also known as the fat burning peptide, represents a breakthrough in targeted weight loss and body composition optimization
Apovian CM, Aronne LJ, Bessesen DH, et al
Mechanism: What Does BPC 157 Do in the Body
Mechanism of Action Tirzepatide: Dual incretin (GIP + GLP-1) enhanced metabolic impact Wegovy: GLP-1 receptor agonist now with higher receptor engagement Weight Loss Outcomes Tirzepatide: ~22% weight reduction in trials Wegovy 7.2 mg: ~2021% weight reduction The efficacy gap is narrowing significantly Cardiometabolic Profile Wegovy: Strong, established cardiovascular outcome data Tirzepatide: Superior glycemic control and insulin sensitivity Safety & Tolerability Both therapies show dose-dependent GI side effects Overall safety profiles remain comparable The Big Picture We are witnessing a shift from: Single-hormone optimization (high-dose semaglutide) to Multi-hormone targeting (tirzepatide) Conclusion While Wegovy is rapidly closing the efficacy gap with dose escalation, Tirzepatide continues to lead as a next-generation metabolic therapy
For Use Under Medical Supervision Only: Consult your doctor or dermatologist before beginning any injectable skincare treatment, especially if you are currently on medication or have underlying health conditions
It is widely used in laboratory experiments
